Good morning :)
$
₹
Profound Medical Corp

Profound Medical Corp

PROF

NASDAQ
Asset Logo

Profound Medical Corp

PROF

NASDAQ
$5.560.05% (+0.00)
$
₹
$5.560.05% (+0.00)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Devices

Micro Cap

With a market cap of $203.2M the stock is ranked 4190

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

4.06
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.99
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-171.56%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 5 analysts reports

Buy
5 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+100.36%

Earnings Growth

+40.6%

Rev. Growth

+128.12%

See Detailed Forecast

Company Profile

Company Profile

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
38.55
38.55
1Y Return
18.86%
18.86%
Buy Reco %
85.71
85.71
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
38.16
38.16
1Y Return
3.48%
3.48%
Buy Reco %
83.33
83.33
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
54.69
54.69
1Y Return
17.95%
17.95%
Buy Reco %
76.47
76.47
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
23.44
23.44
1Y Return
1.27%
1.27%
Buy Reco %
66.66
66.66
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
31.82
31.82
1Y Return
19.81%
19.81%
Buy Reco %
79.31
79.31
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 100.36% growth, versus a trailing 3-year CAGR of -14.03%.

2026
Current$5.56Baseline
Analyst Target - 1 year
Target$11.14+100.36%

All values in $

202220232024202520262027$6.82$8.63$10.44Target+100.36%
2026
Current$5.56Baseline
Analyst Target - 1 year
Target$11.14+100.36%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 128.12% growth, versus a trailing 3-year CAGR of 34.84%.

2025
Current$16.37Baseline
Forecast for Dec 2026
High$40.48+147.19%
Average$37.36+128.12%
Low$34.98+113.57%

All values in $ Million

2021202220232024202520266.876.687.1910.1616.37Low+113.57%Average+128.12%High+147.19%
2025
Current$16.37Baseline
Forecast for Dec 2026
High$40.48+147.19%
Average$37.36+128.12%
Low$34.98+113.57%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-1.41Baseline
Forecast for Dec 2026
High$-0.82+41.84%
Average$-0.84+40.6%
Low$-0.86+39.01%

All values in $

202120222023202420252026-1.5-1.38-1.35-1.12-1.41Low+39.01%Average+40.6%High+41.84%
2025
Current$-1.41Baseline
Forecast for Dec 2026
High$-0.82+41.84%
Average$-0.84+40.6%
Low$-0.86+39.01%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

5.2
-7.9
5.9
-8.1
5.2
-6.9
2.4
-9.5
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue1.432.232.834.052.622.215.285.975.262.48
Net Income-6.58-6.91-9.36-5.33-10.72-15.69-7.97-8.17-6.95-9.54
Net Profit Margin-457.60%-309.85%-330.68%-131.40%-409.15%-709.85%-150.82%-136.77%-132.15%-384.21%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Profound Medical Corp -4.06-
Abbott Laboratories38.553.572.12
Danaher Corporation38.162.951.32
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare PROF with any stock or ETF
Compare PROF with any stock or ETF
Comparing from
PROF
ABT
DHR
Loading...

Frequently asked questions

  1. Profound Medical Corp (PROF) share price today is $5.56 as of October 27, 2026 at 1:29 AM IST. The stock touched a day high of $5.64 and a day low of $5.46.

  2. Profound Medical Corp stock trades on NASDAQ under the ticker symbol PROF.

  3. Profound Medical Corp's market capitalization is $203.16M as of October 27, 2026 at 1:29 AM IST.

  4. Profound Medical Corp's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. Profound Medical Corp's price-to-book (P/B) ratio is 4.06 as of October 26, 2026.

  6. Yes, You can buy Profound Medical Corp shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Profound Medical Corp shares in three steps: 1. Search Profound Medical Corp on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Profound Medical Corp trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Profound Medical Corp (PROF) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.7975 shares at the current price of $5.56.

Loading...